AstraZeneca to Invest $50 Billion in U.S. Manufacturing as Tariff Threats Loom
Summary:
AstraZeneca accelerates a massive $50 billion U.S. manufacturing expansion as Trump’s threatened 200% pharmaceutical tariffs force industry-wide supply chain restructuring.
The Sarepta Reckoning: How Elevidys Crisis Rewrites Gene Therapy’s Risk-Benefit Calculus
Summary:
Sarepta’s unprecedented standoff with the FDA over Elevidys following three deaths has triggered a 500-person layoff, clinical trial suspensions, and fundamental questions about gene therapy oversight in rare diseases.
FDA’s Hardened Stance Claims Another Victim as Replimune Crashes
Summary:
Replimmune’s shares plummeted 75% after the FDA unexpectedly rejected its viral melanoma therapy RP1, with analysts attributing the surprise decision to new CBER Director Vinay Prasad’s stricter stance on uncontrolled trial data.
The Fractional Revolution: Biopharma Talent Reshapes Careers Amid Industry Upheaval
Summary:
With 22% of biopharma professionals have had/been taking fractional roles and 54% considering them, industry experts say the trend reflects both tough job market realities and companies’ need for flexible, senior-level expertise amid funding constraints.
Webinar: Pharma Industry in Crisis – Navigating the New Funding Reality
Summary:
As venture funding tightens in the post‑COVID era, efficiency is now mission‑critical. In this BioSpace Insights webinar (July 16, 2025), experts from Evotec – including Marina Galvani and Josh Gillum – share tangible strategies to uphold drug-development quality under financial pressure.
